151 related articles for article (PubMed ID: 35857415)
1. Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
Bhatt A; Bhandoria G; Kepenekian V; Bakrin N; Glehen O
Int J Cancer; 2022 Dec; 151(11):2055-2056. PubMed ID: 35857415
[No Abstract] [Full Text] [Related]
2. Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
Koole SN; Schouten PC; van Driel WJ; Sonke GS; Linn SC
Int J Cancer; 2022 Dec; 151(11):2057-2058. PubMed ID: 35857410
[No Abstract] [Full Text] [Related]
3. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Koole SN; Schouten PC; Hauke J; Kluin RJC; Nederlof P; Richters LK; Krebsbach G; Sikorska K; Alkemade M; Opdam M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; Mom CH; Arts HJG; van Ham M; van Dam P; Vuylsteke P; Sanders J; Horlings HM; van de Vijver KK; Hahnen E; van Driel WJ; Schmutzler R; Sonke GS; Linn SC
Int J Cancer; 2022 Oct; 151(8):1394-1404. PubMed ID: 35583992
[TBL] [Abstract][Full Text] [Related]
4. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
[TBL] [Abstract][Full Text] [Related]
6. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Schwameis R; Chiva L; Harter P
Int J Gynecol Cancer; 2022 Apr; 32(4):578. PubMed ID: 35121632
[No Abstract] [Full Text] [Related]
7. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer].
Schmalfeldt B
Chirurgie (Heidelb); 2022 Dec; 93(12):1144-1151. PubMed ID: 36201013
[TBL] [Abstract][Full Text] [Related]
8. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
de Bree E; Michelakis D
Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer.
Wang JY; Gross M; Urban RR; Jorge S
Curr Treat Options Oncol; 2024 Mar; 25(3):313-329. PubMed ID: 38270801
[TBL] [Abstract][Full Text] [Related]
10. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
12. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
Gadducci A; Cosio S; Lippolis PV
Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
[TBL] [Abstract][Full Text] [Related]
13. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
Gruner M; Chambers LM; Yao M; Chichura A; Morton M; Costales AB; Horowitz M; Rose PG; Debernardo R; Michener CM
Gynecol Oncol; 2021 Sep; 162(3):645-651. PubMed ID: 34247768
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer.
Gajarawala S; Pelkowski J; Dorian R; Stanton A; Dinh T
JAAPA; 2021 Aug; 34(8):50-53. PubMed ID: 34320542
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
Kim JH; Chun SY; Lee DE; Woo YH; Chang SJ; Park SY; Chang YJ; Lim MC
Gynecol Oncol; 2023 Mar; 170():19-24. PubMed ID: 36608383
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: current evidence-based indications.
Pareja R
Int J Gynecol Cancer; 2023 May; 33(5):841-842. PubMed ID: 36963802
[No Abstract] [Full Text] [Related]
17. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
[TBL] [Abstract][Full Text] [Related]
18. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
19. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?
Alter R; Turaga K; Lengyel E
JAMA Netw Open; 2020 Aug; 3(8):e2014184. PubMed ID: 32840618
[No Abstract] [Full Text] [Related]
20. Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.
Wethington SL; Armstrong DK; Johnston FM
JAMA Surg; 2022 May; 157(5):383. PubMed ID: 35262650
[No Abstract] [Full Text] [Related]
[Next] [New Search]
